Next Phase Newsletter

A venture capital firm with offices in the U.S. and Europe, with a dual-fund structure, invests across several industries, with one of its focuses in healthtech and medtech. The firm’s sweet spot on early-stage companies, focused on Pre-seed to Series A, with potential follow-on investment in Series B. Typical check sizes range from $ 500K – $ 3M. Geographically, the firm is open to opportunities globally and does not have a preference for leading or co-investing in rounds. 

Within life science and healthcare, the firm is interested in Medical Devices through a 4-Pillar focus: (1) Early detection technologies, (2) Robotics, automation, precision medicine, and minimally invasive devices, (3) Digital health and applications, (4)  Brain–computer interface 

Traditional biotech therapeutics is generally not of interest. The firm is agnostic in terms of indications/disease areas. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A French venture capital firm historically focused on deep-tech and hardware but is now broadening their scope to sectors such as the intersection between deep-tech and life sciences. Currently investing from their second fund of USD $75M, the firm participates in Pre-Seed and Seed rounds, typically allocating between USD $500K – $2.5M. The firm prefers to lead or co-lead and looks at companies in Europe and the U.S. 

In terms of life sciences, the firm is open to digital health deep-tech companies but are not interested in apps. The firm does not look at traditional therapeutics but will look at therapeutics with a data component or multi-asset and platform technologies. The firm is also open to diagnostics, non-invasive medical devices, surgical tools, and biomanufacturing. The firm looks at companies that are in their pre-clinical and development stages. The firm is disease-agnostic. 

The firm may take a board or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm founded in 2024 and has USD $40M under management seeks to invest in Pre-Seed and Seed stage longevity biotech companies developing technologies that can significantly extend healthy human lifespan and are scalable for everyone. Initial check size ranges between USD $250K – $1.5M with the ability to lead or co-lead. The firm is open to global companies but prefers the US, UK, and EU. 

The firm is open to all technologies, except single assets, that address longevity. Areas of interest include breakthroughs in multiple areas including AI, synthetic biology, stem cell therapies, gene sequencing and editing, protein engineering, tissue engineering, and more. Every company they invest in must have the potential to extend healthy human lifespan by at least 10+ years. Companies of interest are typically still in pre-clinical stages. The firm seeks out companies with a strong ethical foundation and robust scientific backing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture studio and accelerator that was created as a joint venture between a traditional VC firm and CRO identifies promising early-stage technologies with academic institutional foundations that are not yet ready for institutional investment. The group provides hands-on operational expertise and up to $5M of funding per company to help translate these innovations into viable startups. 
 
In their model, the institutional principal investigators are positioned as company founders, while the group’s CEO and CSO serve as interim executives to help guide early development in conjunction with the broader team. Once the company demonstrates sufficient progress, the VC firm that backs the group would plan to lead a Series A financing. 
 
The group is evolving its traditional venture studio approach to work with early-stage companies that have already been incorporated, and which would benefit from the same operational and strategic support and funding to accelerate achievement of proof of concept and enable access to VC funding or pharma partnerships. The group is currently focused on technologies and companies that are based in the U.S. 

The group focuses exclusively on traditional therapeutics. Although modality-agnostic, the group prefers traditional modalities such as small molecules and biologics. In terms of indication areas, there is particular interest in oncology, kidney disease, fibrosis, immunology and inflammation, and cardiovascular disease. However, the group remains open to other opportunities that address compelling unmet needs and present a sizeable market opportunity. The group targets early programs and considers in-clinic assets to be too late-stage for its investment model. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology